Long-term safety and efficacy of deferasirox (Exjade®) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease

To date, there is a lack of long-term safety and efficacy data for iron chelation therapy in transfusion-dependent patients with sickle cell disease (SCD). To evaluate the long-term safety and efficacy of deferasirox (a once-daily oral iron chelator), patients with SCD completing a 1-year, Phase II,...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Vichinsky, Elliott, Bernaudin, Françoise, Forni, Gian Luca, Gardner, Renee, Hassell, Kathryn, Heeney, Matthew M, Inusa, Baba, Kutlar, Abdullah, Lane, Peter, Mathias, Liesl, Porter, John, Tebbi, Cameron, Wilson, Felicia, Griffel, Louis, Deng, Wei, Giannone, Vanessa, Coates, Thomas
Format: Artigo
Sprache:Inglês
Veröffentlicht: Blackwell Publishing Ltd 2011
Schlagworte:
Red Cells and Iron
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3170481/
https://ncbi.nlm.nih.gov/pubmed/21592110
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2141.2011.08720.x
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge